PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients

被引：0
|
作者：
Ming Chen
Jinlian Zhu
Xuedong Yang
Jianxin Yao
Yuqing Liu
Qiang Liu
机构：
[1] Changshu No.2 People’s Hospital,Department of Hematology
[2] Changshu No.2 People’s Hospital,Department of Oncology
[3] Changshu No.1 People’s Hospital,Department of Hematology
来源：
European Journal of Medical Research | / 27卷
关键词：
Relapsed/refractory multiple myeloma; T cell subtype; PD-1; LAG-3;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
    Siegel, David S.
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Baz, Rachid
    Richardson, Paul
    Delforge, Michel
    Song, Kevin W.
    San Miguel, Jesus F.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Jagannath, Sundar
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Zaki, Mohamed
    Palumbo, Antonio
    LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2833 - 2838
  • [42] TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
    Forster, M.
    Krebs, M.
    Majem, M.
    Peguero, J.
    Clay, T.
    Felip, E.
    Iams, W.
    Roxburgh, P.
    Doger, B.
    Bajaj, P.
    Kefas, J.
    Scott, J. A.
    Joaquin, A. Barba
    Mueller, C.
    Triebel, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S395 - S395
  • [43] Randomized Clinical Trial (RCT) Representativeness and Outcomes Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated in the Real World (RW): Comparison of ASPIRE, TOURMALINE MM1, POLLUX, AND ELOQUENT-2 RCTS
    Chari, Ajai
    Romanus, Dorothy
    Farrelly, Eileen
    Huang, Hui
    Blazer, Marlo
    Raju, Aditya
    Noga, Stephen
    Skacel, Tomas
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S249 - S249
  • [44] Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade
    Niu, Bailin
    Zhou, Fachun
    Su, Yanxin
    Wang, Long
    Xu, Yuanyuan
    Yi, Ziying
    Wu, Yushen
    Du, Huimin
    Ren, Guosheng
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [45] Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
    Poenisch, Wolfram
    Heyn, Simone
    Beck, Juliane
    Wagner, Ina
    Mohren, Martin
    Hoffmann, Franz A.
    Lange, Thoralf
    Schmalfeld, Marion
    Zehrfeld, Thomas
    Schwarzer, Andreas
    Winkelmann, Cornelia
    Edelmann, Thomas
    Roehrborn, Ramona
    Hebenstreit, Karin
    Al-Ali, Haifa K.
    Jaekel, Nadja
    Niederwieser, Dietger
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (02) : 202 - 209
  • [46] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Nooka, Ajay K.
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Bhutani, Manisha
    Oriol, Albert
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Huang, Lin
    Vishwamitra, Deeksha
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S548 - S548
  • [47] Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
    Emiliano Barbieri
    Monica Maccaferri
    Giovanna Leonardi
    Francesca Giacobbi
    Giorgia Corradini
    Ivana Lagreca
    Patrizia Barozzi
    Leonardo Potenza
    Roberto Marasca
    Mario Luppi
    Annals of Hematology, 2022, 101 : 2777 - 2779
  • [48] Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
    Barbieri, Emiliano
    Maccaferri, Monica
    Leonardi, Giovanna
    Giacobbi, Francesca
    Corradini, Giorgia
    Lagreca, Ivana
    Barozzi, Patrizia
    Potenza, Leonardo
    Marasca, Roberto
    Luppi, Mario
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2777 - 2779
  • [49] Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
    Rodriguez-Otero, Paula
    Schinke, Carolina
    Chari, Ajai
    Lipe, Brea
    Lavi, Noa
    Rasche, Leo
    Vishwamitra, Deeksha
    Skerget, Sheri
    Verona, Raluca
    Ma, Xuewen
    Khedkar, Sheetal
    Hilder, Brandi
    Masterson, Tara
    Campagna, Michela
    Renaud, Thomas
    Tolbert, Jaszianne
    Heuck, Christoph
    Smit, M. Damiette
    van de Donk, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S480 - S480
  • [50] A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma
    Cornell, Robert F.
    Bishop, Michael R.
    Kumar, Shaji
    Giralt, Sergio A.
    Nooka, Ajay K.
    Larson, Sarah M.
    Locke, Frederick L.
    Raje, Noopur S.
    Lei, Lei
    Dong, Jinghui
    Gall, John B. Le
    Rossi, John M.
    Orlowski, Robert Z.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 3285 - 3293
12345